The Analgesic Effects of Melatonin
Launched by LARS PETER HOLST ANDERSEN · Aug 15, 2013
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy males aged between 20 and 40 years
- Exclusion Criteria:
- • Under aged/minors
- • Does not speak or understand danish
- • Alcohol or abuse of medicines
- • Prior QST-trial within the last 2 month
- • Prior medical trail within the last month
- • Serious comorbidity (ASA-class 3-4)
- • Chronic pain (defined by analgesic treatment) Shift-work or night work within the last 14 days Known sleep-disorder
About Lars Peter Holst Andersen
Lars Peter Holst Andersen is a distinguished clinical trial sponsor recognized for his commitment to advancing medical research and improving patient outcomes. With a strong background in clinical medicine and a focus on innovative therapeutic approaches, he leads initiatives that prioritize scientific rigor and ethical standards. His collaborative work with multidisciplinary teams fosters the development of novel treatments, ensuring that clinical trials are conducted efficiently and effectively. Through his leadership, Lars Peter Holst Andersen aims to contribute significantly to the field of healthcare by bridging the gap between research and practical application.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Lars P.H. Andersen, MD
Principal Investigator
Herlev Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials